Toyocamycin
Product Specifications
UNSPSC Description
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM[1][2][3].
Target Antigen
Antibiotic; Apoptosis; CDK; Fungal; IRE1
Type
Natural Products
Related Pathways
Anti-infection;Apoptosis;Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/toyocamycin.html
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C3=C(C(N)=NC=N3)C(C#N)=C2
Molecular Weight
291.26
References & Citations
[1]Toyocamycin, et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012 Jul;2(7):e79.|[2]Pandey S, et al. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers (Basel). 2022 Jul 8;14(14):3340. |[3]Park SG, et al. Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells. Pharmacol Rep. 2017 Feb;69(1):90-96.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-103248/Toyocamycin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-103248/Toyocamycin-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
606-58-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
